TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04183712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and oxaliplatin.
Description: GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and oxaliplatin.
Description: GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Target therapy Drug: afatinib
Study: NCT02371304

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Additional TME surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT03321955

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor
Description: Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
Study: NCT00846313

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual dietary counseling.
Description: Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
Study: NCT06369090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography (EIT)
Description: Non-invasive, radiation-free bedside lung monitoring using small alternating currents with no known side effects.
Study: NCT03872869

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip school or Tai CHi for arthritis
Description: Eighty-nine individuals were randomized to one of the three intervention groups 30 individuals to Tai Chi,30 individuals to Hip School and 29 individuals to the control group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip school or Tai CHi for arthritis
Description: Eighty-nine individuals were randomized to one of the three intervention groups 30 individuals to Tai Chi,30 individuals to Hip School and 29 individuals to the control group
Study: NCT00691301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study: NCT02364492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAG-TN3 + AS15
Study: NCT01489397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocol laser endomicroscopy
Description: Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Confocol laser endomicroscopy
Description: Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
Study: NCT00436241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 iv on day 1 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid on days 1-10 of each 2 week cycle
Study: NCT02904889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stay Active at Home
Description: Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Homecare professionals will get no training and their clients will receive usual homecare.
Study: NCT04216966

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No intervention was given

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gracey Curette
Description: Lingual surface of tooth was debrided by Gracey Rigid curette

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: After Five
Description: Lingual surface of tooth was debrided by After Five Rigid curette

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini Five
Description: Lingual surface of tooth was debrided by Mini Five Rigid curette
Study: NCT01848496

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival displacement
Description: Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingival displacement
Description: Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
Study: NCT03363269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID1201

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ID1201
Study: NCT04521660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: Virtual reality (VR) is a new method that can be used to distract and prepare patients for the procedure during medical procedures. It is an advanced technology that allows the individual to move into a virtual environment and focus his attention on other thoughts to less consideration for pain and anxiety. In this study, VR glasses will be worn on the intervention group just before the procedure begins and patients will continue to wear their glasses until the procedure is completed.
Study: NCT00491764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 56592
Description: Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
Study: NCT02048709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0919
Description: Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
Study: NCT03960619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coping skills training
Description: We aim to test a combined coping skills training and activity coaching protocol that: first, is feasible and acceptable, and second, improves physical disability, as well as pain, fatigue, distress, and physical activity in HCT patients. We propose a novel intervention protocol that uses a hybrid in-person and mHealth intervention delivery model.
Study: NCT00906282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 IV over 10 minutes on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 IV on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
Study: NCT03944343

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cereal based products
Description: The cereal products are made from common Swedish cereals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal based products
Description: The cereal products are made from common Swedish cereals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal based products
Description: The cereal products are made from common Swedish cereals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal based products
Description: The cereal products are made from common Swedish cereals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal based products
Description: The cereal products are made from common Swedish cereals.
Study: NCT00491764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 56592
Description: Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 56592
Description: Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 56592
Description: Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: Terbinafine 250 mg QD for 12 weeks.
Study: NCT00573703

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Burch colposuspension
Description: Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transobturator tape procedure
Description: Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
Study: NCT03357224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Patients will receive atezolizumab 1200 mg IV Q3w for 1 year.
Study: NCT04566874

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ALIF
Description: Anterior Lumbar Interbody Fusion

Intervention type: DEVICE
Group type: OTHER
Intervention: ALIF
Description: Anterior Lumbar Interbody Fusion
Study: NCT02294643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarpogrelate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Sarpogrelate)
Study: NCT04671108

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)
Description: Daily disposable contact lens wear for 1 week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)
Description: Daily disposable contact lens wear for 1 week
Study: NCT04243343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention + Standard of care
Description: Acupuncture with electrostimulation plus standard of care prescribed home exercise program for treatment of plantar fasciosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care prescribed home exercise program for treatment of plantar fasciosis.
Study: NCT03425162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: patient-controlled analgesia (PCA) morphine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Morphine Sulfate
Description: patient-controlled analgesia (PCA) morphine

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Group P
Description: Group P:patient-controlled analgesia (PCA) morphine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 Bupivacaine
Study: NCT04181931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neo-TACE-HAIC+Surgery
Description: transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone
Description: hepatic resection remove the liver tumor and portal vein tumor thrombus
Study: NCT02837237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.~In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session.
Study: NCT00436137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient mailing
Description: Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
Study: NCT03264456

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F] Fluciclovine PET/MRI
Description: \[18F\] fluciclovine PET/MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] fluciclovine
Description: \[18F\] fluciclovine
Study: NCT02784327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRF110
Study: NCT02078934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Gastric Plication
Description: Evaluate the efficacy of endoscopic suturing for weight loss
Study: NCT03234816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.05 mcg /Kg/min
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.1 mcg /Kg/min
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.15 mcg /Kg/min
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
Study: NCT00491764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 24 weeks.
Study: NCT02675985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Early Intensive Physical therapy in the ICU
Study: NCT02607930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/DTG/3TC
Description: 600/50/300 milligrams (mg) tablets administered orally, once daily
Study: NCT03234816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 10 mg Bupivacaine intra-thecal for spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 10 mg Bupivacaine intra-thecal for spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 10 mg Bupivacaine intra-thecal for spinal anesthesia
Study: NCT02967237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (U300)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT02607930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally, once daily, without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally, once daily, without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally, once daily, without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC Placebo
Description: Tablets administered orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF Placebo
Description: Tablets administered orally, once daily
Study: NCT00354887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral capecitabine 750 mg/m\^2 twice daily (total daily dose 1500 mg/m\^2) on Days 1-14 in 21 Day Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 by vein Day 1 over 2 hours in 21 Day Cycle
Study: NCT02110238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supartz
Description: Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Euflexxa
Description: Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
Study: NCT04076878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mollii
Description: The Mollii method is provided in a tight fitting, whole body suit with multiple electrodes that can be set individually. The Mollii method uses low frequencies and low intensities that evokes sensory input but does not directly elicit muscle contractions. The theoretical background of this treatment method primarily refers to the concept of reciprocal inhibition, i.e. that sensory input from a muscle may inhibit the activation of an antagonistic muscle through the activation of the disynaptic reciprocal Ia inhibitory pathway.
Study: NCT04403360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPB
Description: Ultrasound guided performance of ESPB at T12 level after the induction of anesthesia but before the start of the surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration by the surgeon
Description: Local infiltration of anesthetics at surgical site after skin incision
Study: NCT03967301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Intervention: defined as probiotic consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consumption. The placebo will be provided by the company that produces the probiotic.
Study: NCT02123342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise programme plus SMS reminders
Description: Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
Study: NCT02877134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 Subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 Subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 Subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 Subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 Subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 Subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo Subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo Subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive ustekinumab as per the dosing regimen.
Study: NCT01146990

Intervention type: DRUG
Intervention: ASQ-3, Bayley III, Neurologic exam
Description: Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
Study: NCT04261036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 1000 mg
Description: 1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills for 14 days post-op after an elective gynecological surgery.
Study: NCT03515083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alive Cor Kardia mobile electrocardiogram monitor
Description: Mobile ECG monitor paired with smart phone application
Study: NCT01500031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OffRoad Re-entry Catheter System
Description: Facilitate the placement and positioning of guidewires within the peripheral vasculature.
Study: NCT02420522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: A non-invasive method of brain stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: A non-invasive method of brain stimulation.
Study: NCT03764943

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Advanced Recovery
Description: immunonutrition shake; nutritional supplement containing amino acids, omega-3 fatty acids, and nucleotides
Study: NCT02506673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeiss, Cinema ProMED (audiovisual equipment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT02420522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: A non-invasive method of brain stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Magnetic Stimulation
Description: A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Magnetic Stimulation
Description: A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
Study: NCT01414660

Intervention type: PROCEDURE
Intervention: transplantation
Description: transplantation of islet, kidney or liver

Intervention type: PROCEDURE
Intervention: transplantation
Description: transplantation of islet, kidney or liver

Intervention type: PROCEDURE
Intervention: transplantation
Description: transplantation of islet, kidney or liver
Study: NCT05857059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 25 mcg
Description: Misoprostol 50 mcg every 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 mcg
Description: Misoprostol 50 mcg every 2 hours